Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Scientists identify KRAS rearrangements in metastatic prostate cancer

AACR 2011

Published: 15 Apr 2011

Views: 5678

Rating:

Save

Prof Arul Chinnaiyan - University of Michigan Medical School, USA

Findings published in Cancer Discovery have revealed a genetic characteristic of metastatic prostate cancer that defines a rare sub-type of this disease. Prof Arul Chinnaiyan and colleagues identified an oncogenic gene fusion of KRAS, one of the most studied and well-known oncogenes in a metastatic prostate cancer cell line. As scientists learn more about the genetic characteristics of this disease, they may be able to work backward and accurately predict which early-stage prostate cancers will be more aggressive and thus require additional therapy and management.

Related Videos

ESMO 2024: Optimising the personalisation of prostate cancer treatment

Prof Alison Birtle, Dr Alejo Rodríguez-Vida, Dr Pasquale Rescigno and Prof Gunhild von Amsberg

ESMO 2024: Optimising the personalisation of prostate cancer treatment ( Prof Alison Birtle, Dr Alejo Rodríguez-Vida, Dr Pasquale Rescigno and Prof Gunhild von Amsberg )

Best practice in HRRm testing in patients with metastatic prostate cancer

Prof Martin Schostak, Dr Alexander Wyatt, Prof Charles Ryan and Dr Emmanuel Antonarakis

Best practice in HRRm testing in patients with metastatic prostate cancer ( Prof Martin Schostak, Dr Alexander Wyatt, Prof Charles Ryan and Dr Emmanuel Antonarakis )

Looking at real world evidence on PSA testing in prostate cancer

Dr Friederike Schlurmann, Prof Boris Hadaschik and Prof Karim Fizazi

Looking at real world evidence on PSA testing in prostate cancer ( Dr Friederike Schlurmann, Prof Boris Hadaschik and Prof Karim Fizazi )

Remote genetic testing has the potential to increase the uptake of testing in large integrated healthcare systems

Dr Bruce Montgomery - University of Washington, Seattle, USA

Remote genetic testing has the potential to increase the uptake of testing in large integrated healthcare systems ( Dr Bruce Montgomery - University of Washington, Seattle, USA )

Stockholm3 offers a promising avenue for personalised risk-based prostate cancer diagnosis

Dr Scott Eggener - The University of Chicago, Chicago, USA

Stockholm3 offers a promising avenue for personalised risk-based prostate cancer diagnosis ( Dr Scott Eggener - The University of Chicago, Chicago, USA )

Baseline characteristics of patients with PSMA-PET–positive and –negative disease with high-risk BCR after radical RP

Prof Boris Hadaschik - University of Duisburg-Essen, Essen, Germany

Baseline characteristics of patients with PSMA-PET–positive and –negative disease with high-risk BCR after radical RP ( Prof Boris Hadaschik - University of Duisburg-Essen, Essen, Germany )

Myeloma treatment and prognosis

Dr Maitreyyee Bhattacharyya - Institute of Hematology and Transfusion Medicine, Kolkata, India

Myeloma treatment and prognosis ( Dr Maitreyyee Bhattacharyya - Institute of Hematology and Transfusion Medicine, Kolkata, India )

Diagnostic performance of 18F-rhPSMA-7.3 PET in newly diagnosed unfavourable intermediate to very high-risk prostate cancer

Prof Tobias Maurer - Martini-Klinik Prostate Cancer Center, Hamburg, Germany

Diagnostic performance of 18F-rhPSMA-7.3 PET in newly diagnosed unfavourable intermediate to very high-risk prostate cancer ( Prof Tobias Maurer - Martini-Klinik Prostate Cancer Center, Hamburg, Germany )

More from ecancer